Seres Therapeutics (MCRB)
NASDAQ:MCRB
Want to see MCRB full AI Analyst Report?
Top Page
Seres Therapeutics
(NASDAQ:MCRB)
Select Model
Select Model
Rating:43Neutral
Price Target:
$7.50
▼(-15.64% Downside)
Action:Upgraded
Date:05/09/26
The score is held down primarily by weak financial performance—large operating losses, heavy ongoing cash burn, and elevated leverage. Technicals add additional pressure with the stock trading below key moving averages and negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and has no stated dividend yield.
Positive Factors
Refocused pipeline & clinical progress
Advancing SER-155 toward Phase 2 readiness and preparing IND-enabling work for SER-603 diversifies Seres’ development-stage assets beyond the divested commercial franchise. Fully enrolled investigator study and near-term data can materially de-risk programs, attract partners, and create multiple development pathways over the next 2–6 months and beyond.
Negative Factors
Sustained high cash burn
Meaningful negative operating and free cash flow reflect an unsustainable burn rate for a small developer absent new funding or partnership support. Continued high burn increases dilution risk and forces timing-sensitive capital raises, constraining strategic options and putting program continuity at risk if additional capital is delayed.
Read all positive and negative factors
Positive Factors
Negative Factors
Refocused pipeline & clinical progress
Advancing SER-155 toward Phase 2 readiness and preparing IND-enabling work for SER-603 diversifies Seres’ development-stage assets beyond the divested commercial franchise. Fully enrolled investigator study and near-term data can materially de-risk programs, attract partners, and create multiple development pathways over the next 2–6 months and beyond.
Read all positive factors
Seres Therapeutics (MCRB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$73.99M
Dividend YieldN/A
Average Volume (3M)45.86K
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue GrowthN/A
EPS Growth49.74%
CountryUS
Employees103
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.18
Shares Outstanding9,683,934
10 Day Avg. Volume44,972
30 Day Avg. Volume45,862
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)2.98
Price to Sales (P/S)167.07
P/FCF Ratio152.39
Enterprise Value/Market Cap1.68
Enterprise Value/Revenue108.67
Enterprise Value/Gross Profit-519.38
Enterprise Value/Ebitda-2.66
Forecast
1Y Price Target
$22.00Price Target Upside147.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-8.23
Revenue Forecast (FY)N/A
Seres Therapeutics Business Overview & Revenue Model
Company Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SE...
How the Company Makes Money
Seres Therapeutics has historically generated revenue primarily from collaboration-related arrangements (e.g., upfront payments, license fees, research and development reimbursements, and potential milestone payments) with larger pharmaceutical pa...
Seres Therapeutics Earnings Call Summary
Earnings Call Date:Nov 05, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Positive
The call highlighted significant clinical progress and financial recovery, supported by external funding and strategic cost reductions. However, the dependency on securing further capital for future studies poses a notable challenge.Positive Updates
SER-155 Clinical Progress
SER-155 Phase Ib study showed a 77% relative risk reduction in bacterial bloodstream infections, decreased antibiotic exposure, and febrile neutropenia. The FDA provided constructive feedback, aligning on key study parameters for the Phase II protocol.
Negative Updates
Dependence on Funding for Phase II Study
The commencement of SER-155 Phase II study is funding dependent, and the company is actively seeking partnerships or other capital sources.
Read all updates
Q3-2025 Updates
Positive
Negative
SER-155 Clinical Progress
SER-155 Phase Ib study showed a 77% relative risk reduction in bacterial bloodstream infections, decreased antibiotic exposure, and febrile neutropenia. The FDA provided constructive feedback, aligning on key study parameters for the Phase II protocol.
Read all positive updates
Company Guidance
During the Q3 2025 call, Seres Therapeutics highlighted significant advancements related to their lead investigational therapy, SER-155. The therapy showed a 77% relative risk reduction in bacterial bloodstream infections in a Phase Ib study and is progressing to a Phase II study. This study, which targets adults undergoing allo-HSCT, has received Breakthrough Therapy designation from the FDA. Seres anticipates obtaining meaningful clinical results from an interim analysis within 12 months of study initiation, contingent upon funding. The company reported a net income of $8.2 million for Q3 2025, compared to a net loss of $51 million in the same quarter of 2024, due in part to a $25 million installment payment from Nestlé. Their cash position as of September 30, 2025, stood at $47.6 million, expected to fund operations through Q2 2026. Additionally, Seres received a $3.6 million non-dilutive grant from CARB-X for developing a liquid formulation of SER-155, with plans to expand its use in other medically vulnerable populations.Seres Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.15M | 789.00K | 0.00 | 0.00 | 0.00 | 144.93M |
| Gross Profit | -240.00K | -3.34M | -3.53M | 0.00 | 0.00 | 144.93M |
| EBITDA | -46.90M | -89.84M | -120.30M | -181.42M | -170.93M | -56.72M |
| Net Income | -46.90M | 5.70M | 136.00K | -113.72M | -250.16M | -65.58M |
Balance Sheet | ||||||
| Total Assets | 117.62M | 138.19M | 139.81M | 358.60M | 348.78M | 354.86M |
| Cash, Cash Equivalents and Short-Term Investments | 29.83M | 45.77M | 30.79M | 127.97M | 181.34M | 290.71M |
| Total Debt | 80.50M | 82.97M | 91.64M | 198.78M | 162.59M | 49.21M |
| Total Liabilities | 91.12M | 93.97M | 126.03M | 403.46M | 338.00M | 223.35M |
| Stockholders Equity | 26.50M | 44.22M | 13.78M | -44.86M | 10.78M | 131.51M |
Cash Flow | ||||||
| Free Cash Flow | -42.37M | 865.00K | -148.99M | -125.33M | -238.64M | -2.88M |
| Operating Cash Flow | -42.15M | 1.12M | -148.61M | -117.35M | -228.82M | 6.69M |
| Investing Cash Flow | -8.00K | -42.00K | 142.29M | 10.58M | 82.43M | 64.09M |
| Financing Cash Flow | 13.15M | 13.90M | -90.37M | 71.70M | 129.60M | 1.18M |
Seres Therapeutics Technical Analysis
Neutral
8.89
Price Trends
9.33
Negative
12.59
Negative
14.73
Negative
Market Momentum
-0.22
Negative
47.68
Neutral
57.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MCRB, the sentiment is Neutral. The current price of 8.89 is above the 20-day moving average (MA) of 8.80, below the 50-day MA of 9.33, and below the 200-day MA of 14.73, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 47.68 is Neutral, neither overbought nor oversold. The STOCH value of 57.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MCRB.
Seres Therapeutics Risk Analysis
Seres Therapeutics disclosed 67 risk factors in its most recent earnings report. Seres Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Seres Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $73.99M | -1.07 | -127.30% | ― | ― | 49.74% | |
| ― | $94.55M | -9.85 | -65.55% | ― | ― | 19.02% | |
52 Neutral | $102.03M | -3.71 | -72.68% | ― | ― | 64.57% | |
47 Neutral | $223.80M | -3.48 | -194.74% | ― | 160.53% | 12.32% | |
45 Neutral | $326.83M | -0.63 | 309.79% | ― | -35.61% | -68.92% |
* Healthcare Sector Average
MCRB
Seres Therapeutics
7.64
-0.34
-4.26%
ANIX
Anixa Biosciences
2.82
0.12
4.44%
SRZN
Surrozen
28.15
20.12
250.56%
CGTX
Cognition Therapeutics
1.14
0.81
245.45%
IMMX
Immix Biopharma
9.94
7.83
371.09%
CAMP
CAMP4 Therapeutics Corporation
4.31
2.12
96.80%
Seres Therapeutics Corporate Events
Regulatory Filings and ComplianceShareholder Meetings
Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date
Neutral
Mar 16, 2026
Seres Therapeutics, Inc. announced that its 2026 annual meeting of stockholders is scheduled for June 9, 2026, with shareholders of record as of the close of business on April 13, 2026 entitled to vote. The company noted that, because this meeting...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Seres Therapeutics Reports 2025 Results, Highlights Refocused Pipeline
Neutral
Mar 12, 2026
Seres Therapeutics reported its fourth-quarter and full-year 2025 financial results on March 12, 2026, alongside updates on its refocused pipeline in inflammatory and immune diseases. The company posted a modest net income of $5.7 million from con...
Business Operations and StrategyExecutive/Board Changes
Seres Therapeutics Announces Executive Leadership Changes and Promotions
Neutral
Mar 2, 2026
On February 27, 2026, Seres Therapeutics’ board named director Richard N. Kender as Executive Chair and Interim CEO, effective March 2, 2026, while promoting Chief Scientific Officer Matthew Henn to President and Senior Vice President of Cli...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.